Key information

Title
Piscine Orthoreovirus Virulence Markers
Application number
20190110
Case type
National
Status
Filed
30.01.2019
Effective date
30.01.2019
Publicly available
31.07.2020
Next annual fee due
31.01.2027
Applicant
PatoGen AS (NO)
Owner
PatoGen AS (NO)
Inventor
Morten Lund (NO) et al.
Agent
ACAPO ONSAGERS AS (NO)
Granted
03.08.2020
Patent number
344967
Expiry date
30.01.2039

Abstract and drawing


Disclaimer: This text has been machine-scanned and may contain errors – please refer to "Publications" for legally binding content.
The invention relates to methods for determining virulence of PRV in a biological sample from a fish, comprising detection of SNPs. The invention further relates to primers and probes to be used in such a method.

Publications


B1A1
Checking availability of the latest published version...

Documents


Expand Download files (35)
Date
Date Doc. No. Process Case number In/Out Journal description To/from
06.07.2021 16-02 Saksbehandling 20190110(344967) INN PDF_437765024 ACAPO AS
06.07.2021 16-01 Saksbehandling 20190110(344967) INN Korrespondanse (Hovedbrev inn) ACAPO AS
27.01.2021 15-01 Saksbehandling 20190110(344967) INN Patentsøknad 2019 0110
01.12.2020 14-01 Saksbehandling 20190110(344967) UT PT Varsel om betaling av første årsavgift (3317) (PT20190110)
10.08.2020 13-01 Saksbehandling 20190110 UT PT Registreringsbrev Nasjonal Patent (15) (PT20190110)
27.07.2020 12-01 Saksbehandling 20190110 UT PT Meddelelse om patent ACAPO AS
13.07.2020 11-05 Saksbehandling 20190110 INN Beskrivelse ren ACAPO AS
13.07.2020 11-04 Saksbehandling 20190110 INN Beskrivelse merket ACAPO AS
13.07.2020 11-03 Saksbehandling 20190110 INN Hovedbrev ACAPO AS
13.07.2020 11-02 Saksbehandling 20190110 INN Krav ACAPO AS
13.07.2020 11-01 Saksbehandling 20190110 INN Korrespondanse (Hovedbrev inn) ACAPO AS
06.05.2020 10-02 Saksbehandling 20190110 INN Hovedbrev ACAPO AS
06.05.2020 10-01 Saksbehandling 20190110 INN Korrespondanse (Hovedbrev inn) ACAPO AS
27.03.2020 09-01 Saksbehandling 20190110 UT PT Meddelelse om patent ACAPO AS
03.02.2020 08-05 Saksbehandling 20190110 INN Krav ACAPO AS
03.02.2020 08-04 Saksbehandling 20190110 INN Beskrivelse ren ACAPO AS
03.02.2020 08-03 Saksbehandling 20190110 INN Hovedbrev ACAPO AS
03.02.2020 08-02 Saksbehandling 20190110 INN Beskrivelse merket ACAPO AS
03.02.2020 08-01 Saksbehandling 20190110 INN Korrespondanse (Hovedbrev inn) ACAPO AS
04.10.2019 07-02 Saksbehandling 20190110 UT PT_report 12:57:48
04.10.2019 07-01 Saksbehandling 20190110 UT Realitet patent ACAPO AS
27.06.2019 05-01 Saksbehandling 20190110 UT Generelt brev Patent uten frist ACAPO AS
20.06.2019 06-03 Saksbehandling 20190110 INN Hovedbrev ACAPO AS
20.06.2019 06-02 Saksbehandling 20190110 INN Overdragelsesdokument ACAPO AS
20.06.2019 06-01 Saksbehandling 20190110 INN Korrespondanse (Hovedbrev inn) ACAPO AS
30.04.2019 04-03 Saksbehandling 20190110 INN Overdragelsesdokument ACAPO AS
30.04.2019 04-02 Saksbehandling 20190110 INN Fullmakt ACAPO AS
30.04.2019 04-01 Saksbehandling 20190110 INN Korrespondanse (Hovedbrev inn) ACAPO AS
31.01.2019 03-01 Saksbehandling 20190110 UT Formalia 1 ACAPO AS
31.01.2019 02-01 Saksbehandling 20190110 UT Infobrev til oppfinner ACAPO AS
30.01.2019 01-05 Saksbehandling 20190110 INN Sekvensliste pdf ACAPO AS
30.01.2019 01-04 Saksbehandling 20190110 INN Patenttegninger ACAPO AS
30.01.2019 01-03 Saksbehandling 20190110 INN Beskrivelse ACAPO AS
30.01.2019 01-02 Saksbehandling 20190110 INN Sekvensliste ACAPO AS
30.01.2019 01-01 Saksbehandling 20190110 INN Søknadsskjema Patent ACAPO AS

Description, claims and drawings


Disclaimer: This text has been machine-scanned and may contain errors – please refer to "Publications" for legally binding content. Description
Piscine Orthoreovirus Virulence MarkersThe present invention relates to methods for determining virulence of Piscine orthoreovirus (PRV), and primers and probes to be used in such a method, according to the preamble of the independent patent claims.BackgroundThe aquaculture industry is an important food source and income, and Salmonids in particular are very popular farmed species in many regions of the world. Viral diseases pose a significant threat to the productivity in aquaculture, and thus impact the future global aquaculture production. Heart and Skeletal Muscle Inflammation (HSMI) has become a serious disease in farmed salmonids in several geographical areas. It was discovered in salmon in the sea in Norway in 1999, and is now reported from fresh and seawater sites in for instance UK, Scotland, Canada and Chile. The causal relationship between the PRV and HSMI was described by (Wessel Ø, et al. (2017) Infection with purified Piscine orthoreovirus demonstrates a causal relationship with heart and skeletal muscle inflammation in Atlantic salmon. PLoS ONE 12(8):e0183781). The mortality during HSMI outbreaks varies from negligible to 20 %.According to The National Veterinary Institute the virus has spread over the years and in 2014 the virus was delisted from notifiable diseases. The delisting was done because the PRV is ubiquitous in Atlantic salmon, and thus present also in healthy individuals not associated with clinical disease. Still, HSMI is a significant health problem for the aquaculture industry in Norway, but it is not yet possible to differentiate between virulent and less virulent or non-virulent strains of PRV.Consistent with the genome organization characteristic for members of the family Reoviridae, the genome of the PRV comprises at least 10 RNA segments (GenBank Accession numbers GU994013-GU994022). Reoviruses are non-enveloped icosahedral viruses with double-stranded RNA genomes comprising 10–12 segments. Palacios et al 2010, identified that PRV viral genome consists of 10 different segments; L1, L2, L3, M1, M2, M3, S1, S2, S3 and S4 (Palacios G, et al. (2010) Heart and Skeletal Muscle Inflammation of Farmed Salmon Is Associated with Infection with a Novel Reovirus. PLoS ONE 5(7): e11487).Viruses closely related to PRV from farmed Atlantic salmon have been discovered in association with diseases in other salmonid species, for instance as described in NO20161983 and WO2016/075277. A virus called PRV-2 was demonstrated to be the possible causative agent of erythrocytic inclusion body syndrome (EIBS), a disease that can cause mass mortality in Coho salmon (Oncorhynchus kisutch). Another PRV-like virus was detected in association with a disease outbreak in rainbow trout (Oncorhynchus mykiss) in Norway; the fish displayed signs of circulatory disturbance and histopathological changes resembling HSMI.Furthermore, a PRV strain closely related to the PRV from rainbow trout was found in association with HSMI-like lesions in Coho salmon in Chile. The presence of several PRV variants associated with diseases in salmonids suggests that species adaptation is important for pathogenesis (Wessel 2017).Siah et al 2015 conducted a phylogenetic study of PRV strains from Norway, Canada and Chile, and found that Norwegian strains differed in S1 segment. Wessel et al have shown the genetic relationship of strains from different regions and species, and shows that strains from Atlantic salmon all belong to the same group. Parts of the genome of the Norwegian strain is sequenced, and known for instance from Genbank. However, also in Norway there are fish detected positive to PRV without clinical symptoms, and fish detected positive to PRV developing HSMI.Therefore it is important to have diagnostic tools to differentiate between the strains that can cause disease, and those that do not.The current diagnostic methods are histology, immunohistochemistry, virus propagation and PCR, wherein PCR gives the fastest result and is the preferred method. EP 2482825 describes a known method for determining the presence or absence of piscine reovirus, by using PCR, and WO2018/138527 describes a method of predicting resistance to HSMI in salmonids, comprising determining the alleles present at a DNA polymorphism in the salmonid and predicting whether or not the salmonid is resistant to heart and skeletal muscle inflammation based on the determination of the alleles.The genomes of all organisms undergo spontaneous mutations during their continuing evolution, forming variant forms of progenitor genetic sequences. A mutation may result in an evolutionary advantage or disadvantage relative to a progenitor form or may be neutral. A variant that result in an evolutionary advantage may eventually be incorporated in many members of the species and may thus effectively become the progenitor form. Furthermore, often various variant forms survive and coexist in a species population. The coexistence of multiple forms of a genetic sequence gives rise to genetic polymorphism, including single-nucleotide polymorphisms (SNPs).A single-nucleotide polymorphism (SNP) is a DNA sequence variation occurring when a single nucleotide — A, T, C or G — in the genome (or other shared sequence such as RNA) differs between members of a biological species or paired chromosomes in an organism. For example, two DNA fragments from different individuals, AAGCCTA to AAGCTTA, contain a difference in a single nucleotide, commonly referred as two alleles. Almost all common SNPs have only two alleles. The genomic distribution of SNPs is not homogenous; SNPs usually occur in noncoding regions more frequently than in coding regions or, in general, where natural selection is acting the allele of the SNP that constitutes the most favorable genetic adaptation is predominating.The inventionThe issues set out above are solved by methods, primers and probes according to the characterizing part of the enclosed independent claims. Further advantageous features are stated in the corresponding dependent claims.The present invention relates to a method for determining virulence of Piscine Orthoreovirus (PRV) in a biological sample from a fish, comprising a step for detecting whether any of the following single nucleotide polymorphisms (SNPs) are present in the genomic materialS4-T320C or S4-G754A in SEQ ID NO.4,M2-T580A, or M2-A958G in SEQ ID NO.5,M3-A280T, M3-C371T, M3-C1064T, M3-A1351G, M3-T1421C or M3-T1687C in SEQ ID NO.6,or the complementary oligonucleotides thereof, wherein the numbering of said positions are in accordance with sequences 4, 5, and 6, respectively, wherein presence of at least one SNP confirms that the virus is virulent and will cause morbidity and/or mortality of a fish upon infection.Further SNPs in M2 are also described, but not being a part of the invention as claimed.The SNPs as mentioned above are to be understood as defined in table 1 below.The SNP S4-T320C should thus be understood to mean a mutation from T to C in position 320 of the S4 segment. The reference segment of S4 is shown in SEQ ID NO. 4. Virulence is a measure of the pathogenicity of an organism. The degree of virulence is related directly to the ability of the organism to cause disease despite host resistance mechanisms.In one embodiment, the method further comprises a step for isolating the genomic material from the biological sample, and possibly a step for sequencing the material before detecting the SNPs. The step for detection of the SNPs may be performed in many ways which will be obvious to a skilled person, and the necessity of isolating and sequencing depends on the detection method.In a preferred embodiment, any sequencing, is performed by a polymerase chain reaction and use of at least one primer. The sequencing may also be performed by Next Generation Sequencing Methods, such as a method selected from the group consisting of Illumina (Solexa) sequencing, Roche 454 sequencing, Ion Torrent and SOLiD sequencing.The detection of SNPs may be performed by manual or automatic comparing the sequenced genomic material from the sample with the reference.In a preferred embodiment of the invention, the step of detecting comprises use of a polymerase chain reaction and use of at least one primer and/or probe.In a preferred embodiment, each primer or probe used for sequencing or detecting comprise a sequence of at least 10 consecutive nucleotides selected from one of the sequences of a group consisting of SEQ ID NO.24-26, 28-30, 32-34, 36-38, 40-42, 44-46, 48-50, 52-54, 56-58 and 60-63.In a preferred embodiment, the primers used for sequencing or detecting are used as primer pairs, selected from a group consisting of the following primer pairs: primers according to SEQ ID NO.24 and 25,primers according to SEQ ID NO.28 and 29,primers according to SEQ ID NO.32 and 33, primers according to SEQ ID NO.36 and 37,primers according to SEQ ID NO.40 and 41,primers according to SEQ ID NO.44 and 45,primers according to SEQ ID NO.48 and 49,primers according to SEQ ID NO.52 and 53,primers according to SEQ ID NO.56 and 57, andprimers according to SEQ ID NO.60 and 61.In a preferred embodiment, the step of detecting comprises use of probes, preferably in a PCR reaction, wherein binding of a probe comprising a sequence of at least 10 consecutive nucleotides fromSEQ ID NO.26, confirms the virus to have SNP S4-T320C SEQ ID NO.30, confirms the virus to have SNP S4-G754A SEQ ID NO.34, confirms the virus to have SNP M2-G551C SEQ ID NO.38, confirms the virus to have SNP M2-T580A SEQ ID NO.42, confirms the virus to have SNP M2-G784T SEQ ID NO.46, confirms the virus to have SNP M2-A1108G SEQ ID NO.50, confirms the virus to have SNP M3-A280T SEQ ID NO.54, confirms the virus to have SNP M3-C371T SEQ ID NO.58, confirms the virus to have SNP M3-A1351G SEQ ID NO.62 or 63, confirms the virus to have SNP M3-T1687CThe invention further relates to a method as described above, wherein the presence of mutation M3-A280T and/or M3-A1351G in SEQ ID NO.6 confirms the virus to cause high mortality.The invention further relates to a method as described above, wherein the presence of mutations M3-A280T, M3-C1064T, M3-A1351G, M3-T1421C and M3-T1687C in SEQ ID NO.6 confirm the virus to cause high mortality.The invention further relates to a method as described above, wherein the presence of mutations S4-G754A, M2-T580A, M2-A958G, M3-A280T, M3-C1064T, M3 A1351G, M3-T1421C, and M3-T1687C in SEQ ID NO.6 confirm the virus to cause high mortality.The invention further relates to a method as described above, wherein the presence of mutation M3-C371T in SEQ ID NO.6 confirms the virus to cause moderate to low mortality, and morbidity.The invention further relates to a method as described above, wherein the presence of mutations M3-C371T, M3-C1064T and M3-T1421C in SEQ ID NO.6 confirm the virus to cause moderate to low mortality, and morbidity.The invention further relates to a method as described above, wherein the presence of mutations S4-G754A, M2-A958G, M3-C371T, M3-C1064T, and M3-T1421C in SEQ ID NO.6 confirm the virus to cause moderate to low mortality, and morbidity.The invention further relates to a method as described above, wherein the presence of mutation S4-T320C in SEQ ID NO.4 confirms the virus to cause high morbidity.The invention further relates to a method as described above, wherein the presence of mutations S4-T320C, M2-T580A, M2-A958G, M3-C1064T, M3-T1421C and M3-T1687C in SEQ ID NO.6 confirms the virus to cause high morbidity.The invention further relates to a method as described above, wherein the presence of mutation S4-G754A in SEQ ID NO.4 confirms the virus to cause high to moderate mortality, and morbidity.The invention further relates to a method as described above, wherein the absence of all SNPs mentioned in table 1 above, confirms the virus to be nonvirulent, and not cause mortality or morbidity. In order to prove the absence of all SNPs, a method according to the above may be carried out, comprising use of a primer and probe comprising a sequence of at least 10 consecutive nucleotides according to the following primers acc. to SEQ ID NO.24 and 25, and probe acc. to SEQ ID NO.27, confirm the absence of SNP S4-T320C,primers acc. to SEQ ID NO.28 and 29, and probe acc. to SEQ ID NO.31, confirm the absence of SNP S4-G754A,primers acc. to SEQ ID NO.32 and 33, and probe acc. to SEQ ID NO.35, confirm the absence of SNP M2-G551C,primers acc. to SEQ ID NO.36 and 37, and probe acc. to SEQ ID NO.39, confirm the absence of SNP M2-T580A,primers acc. to SEQ ID NO.40 and 41, and probe acc. to SEQ ID NO.43, confirm the absence of SNP M2-G784T,primers acc. to SEQ ID NO.44 and 45, and probe acc. to SEQ ID NO.47, confirm the absence of SNP M2-A1108G,primers acc. to SEQ ID NO.48 and 49, and probe acc. to SEQ ID NO.51, confirm the absence of SNP M3-A280T,primers acc. to SEQ ID NO.52 and 53, and probe acc. to SEQ ID NO.55, confirm the absence of SNP M3-C371T,primers acc. to SEQ ID NO.56 and 57, and probe acc. to SEQ ID NO.59, confirm the absence of SNP M3-A1351G,primers acc. to SEQ ID NO.60 and 61, and probe acc. to SEQ ID NO.64, confirm the absence of SNP M3-T1687CThe invention also relates to a primer or probe comprising a sequence of at least 10 consecutive nucleotides selected from the group comprising SEQ ID NO.24-26, 28-30, 32-34, 36-38, 40-42, 44-46, 48-50, 52-54, 56-58 and 60-63. The primer or probe may comprise any 10 consecutive nucleotides from SEQ ID NO.24, or from SEQ ID NO. 25, or from SEQ ID NO.26 etc. The primer or probe may also comprise, or be identical to, the mentioned sequences.The invention further relates to a method for determining virulence of Piscine Orthoreovirus (PRV) in a biological sample from a fish, comprising the following steps,a) isolating amino acid sequences of the sample, b) sequencing the amino acid sequence,c) detecting whether any of the following amino acids are present in the amino acid sequences- A in position 107 or N in position 252 of SEQ ID NO.1- I in position 194, or A in position 320 of SEQ ID NO.2, or- L in position 94, V in position 124, L in position 355, V in position 451, T in position 474 or P in position 563 of SEQ ID NO.3wherein the numbering of said positions are in accordance with the sequences SEQ ID NO.1, 2 and 3, respectively,wherein presence of at least one of the amino acids confirms that the virus is virulent and will cause morbidity and/or mortality of the fish upon infection.If none of the following amino acids are present, A in position 107 or N in position 252 of SEQ ID NO.1, T in position 184, I in position 194, S in position 262, A in position 320 or D in position 370 of SEQ ID NO.2, or L in position 94, V in position 124, L in position 355, V in position 451, T in position 474 or P in position 563 of SEQ ID NO.3, then the virus is non-virulent.The invention further relates to a method as described above, wherein the presence of amino acid L in position 94, and/or V in position 451 in SEQ ID NO.3 confirms the virus to cause high mortality.The invention further relates to a method as described above, wherein the presence of L in position 94, L in position 355, V in position 451, T in position 474 and P in position 563 of SEQ ID NO.3 confirms the virus to cause high mortality.The invention further relates to a method as described above, wherein the presence of N in position 252 of SEQ ID NO.1, I in position 194, and A in position 320 of SEQ ID NO.2, and L in position 94, L in position 355, V in position 451, T in position 474 and P in position 563 of SEQ ID NO.3 confirms the virus to cause high mortality. The invention further relates to a method as described above, wherein the presence of V in position 124 of SEQ ID NO.3 confirms the virus to cause moderate mortality, high morbidity.The invention further relates to a method as described above, wherein the presence of V in position 124, L in position 355, and T in position 474 of SEQ ID NO.3 confirms the virus to cause moderate mortality, high morbidity.The invention further relates to a method as described above, wherein the presence of - N in position 252 of SEQ ID NO.1, and A in position 320 of SEQ ID NO.2, and V in position 124, L in position 355, and T in position 474 of SEQ ID NO.3 confirms the virus to cause moderate mortality, high morbidity.The invention further relates to a method as described above, wherein the presence of A in position 107 of SEQ ID NO.1, and I in position 194 and A in position 320 of SEQ ID NO.2, and L in position 355, T in position 474 and P in position 563 of SEQ ID NO.3confirms the virus to cause high morbidity.The invention further relates to a method as described above, wherein the presence of N in position 252 of SEQ ID NO.1 confirms the virus to cause moderate mortality, high morbidity.FiguresThe invention will now be described in detail with reference to the enclosed Figures and sequences whereFig. 1 shows an alignment of PRV protein S4, from GenBank AGR27923 (SEQ ID NO. 1) and from a virulent virus strain (SEQ ID NO.7-8), AGR27923 is cut 17 amino acids at the end,Fig. 2 shows an alignment of PRV Protein M2 (SEQ ID NO.2), from GenBank AGR27919 and from a virulent virus strain (SEQ ID NO.9-10), Fig. 3 shows an alignment of PRV Protein M3 (SEQ ID NO.3), from GenBank AGR27920 and from a virulent virus strain (SEQ ID NO.11-13)Fig. 4 shows an alignment of the nucleotide encoding S4, from GenBank KC715687 (SEQ ID NO.4) and from a virulent virus strain (SEQ ID NO.14-16) KC715687 is cut 38 nucleotides at 5 end and 105 at 3 end,Fig. 5 shows an alignment of the nucleotide encoding M2, from GenBank KC715683 (SEQ ID NO.5) and from a virulent virus strain (SEQ ID NO.17-20) KC715683 is cut with 26 nucleotides at 5 end and 87 at 3 end,Fig. 6 shows an alignment of the nucleotide encoding M3, from GenBank KC715684 (SEQ ID NO.6) and from a virulent virus strain (SEQ ID NO.21-23) KC715684 is cut with 83 nucleotides at 5 end and 60 at 3 end,Fig. 7 shows a phylogenetic tree of S4,Fig. 8. shows accumulated mortality associated with the PRV genotypes of virulent virus, wherein Fig 8.A shows HSMI mortality and Fig 8.B. shows mortality of looser fish also called morbidity.The enclosed nucleotide sequences areDescription of preferred embodiments of the inventionReference throughout the description to "an embodiment" signifies that a particular feature, structure or property specified in connection with an embodiment is included in the least in one embodiment. The expressions "in one embodiment", "in a preferred embodiment" or "in an alternative embodiment" different places in the description does not necessarily point to the same embodiment. Further, the different features, structures or properties may be combined in any suitable way in one or more of the embodiments.Example 1:This study describes different genotypes of PRV isolates collected from farmed Atlantic salmon in Norway.Materials and methodsTissue samples of heart, head or kidney from HSMI diseased farmed Atlantic salmon were collected from aquaculture farms in Norway and tested for PRV by RT-qPCR. The samples were collected from 11 freshwater sites and 29 seawater sites during the years 2014 to 2016. The samples were collected aseptically on tubes prefilled with RNAlater (Ambion, USA). After sampling, the tubes containing tissue samples were shipped chilled to PatoGen AS with 24-hour delivery service.The RT-qPCR assay targeting PRV were performed, the method is validated according to ISO17025 standards and is described elsewhere (Glover et al.2013). Amino acids changes can be detected by different methods as protein sequencing, DNA/RNA sequencing or by Real Time SNP. The two last methods are easier and more cost effective than protein sequencing. In this example DNA/RNA sequencing by Sanger and by Real Time PCR were used.PRV isolates from 3 freshwater sites and 17 seawater sites where the fish had developed HSMI, were selected, the genomic material of the samples were isolated, and the genomic material was sequenced. Further, the amino acid sequences of the sample were isolated and sequenced.A retrospective epidemiological study was performed to investigate whether specific PRV genotypes was associated with HSMI mortality and/or morbidity (including looser fish). The data was collected from salmon farms in Norway. Looser fish is fish not developing and acting normal, it is often smaller than normal fish, has a higher mortality rate and it cannot be sent to the marked once slaughtered. In the following, virus causing looser fish will be referred to as virus causing morbidity.ResultsAll samples confirmed positive to PRV in standard qPCR testing. The phylogenetic analyses generated 3 distinct groups shown as A, B and C in figure 7, in addition to the reference.The genomic material and the amino acid sequences of the sample were compared to a Canadian strain from Genbank named VT06062012-358 (herein called reference or reference virus), defined as non-virulent, whereSEQ ID NO.1 shows a truncated version of the amino acid sequence of S4, being the outer fiber protein, andSEQ ID NO.4 shows a truncated version the nucleotide sequence of the S4 segment, encoding the outer fiber protein,SEQ ID NO.2 shows the amino acid sequence of M2 segment being the outer shell protein, and SEQ ID NO.5 shows a truncated version of the nucleotide sequence of the M2 segment encoding the outer shell protein, andSEQ ID NO.3 shows the amino acid sequence of M3 segment, encoding a nonstructural factory protein, andSEQ ID NO.6 shows a truncated version of the nucleotide sequence of the M3 segment encoding the non-structural factory protein,of the reference virus.Sequences for both the proteins and the nucleotide sequences encoding the proteins were aligned with the reference. The alignments are enclosed as Figure 1 and 4, regarding S4 segment, Figure 2 and 5 regarding M2 segment and Figure 3 and 6 regarding M3 segment. Genotype groups were established, named A, B and C, however in Figure 4, 5 and 6 group A is named Grønn, group B is named Gul and group C is named Rød. In the alignments both SNPs causing an amino acid change and silent mutations are shown.Regarding the S4 segment, the genotype groups A and C of the protein are identical. The sequences of A/C and B are enclosed as SEQ ID NO.7 and 8 respectively. The genotype groups A, B and C of the nucleotide sequence are unique, and enclosed as SEQ ID NO.14-16.Regarding the M2 segment, there were 4 genotype groups, A, A-2, B and C, where the proteins of A-2 and B, and A and C are identical, sequences of which are enclosed as SEQ ID NO.9 and 10, respectively. The groups A, A-2, B and C of the nucleotide sequence are unique, and enclosed as SEQ ID NO.17-20, respectively.Regarding the M3 segment, the genotype groups of the proteins were unique, the sequences are enclosed as SEQ ID NO.11-13, showing genotype group A, B and C respectively. The genotype groups A, B and C of the nucleotide sequence are also unique, and enclosed as SEQ ID NO.21-23, respectively. The three different genogroups identified 13 different unique changes in amino acids that are associated to virulence (Table 2). It is the amino acids that are the basis for the genogrouping. There were slight variations in silent mutations in addition, that did not cause any change in amino acid.Table 2. Amino acid differences identified in PRV strains.In the epidemiological study the accumulated mortality and morbidity (e.g. looser fish) were recorded. The mortality and morbidity observations correlated well with the 3 genogroups A, B and C. The reference was not detected in any of the sites. Six PRV-isolates grouped into genogroup C, 9 PRV-isolates into the genogroup A and 5 PRV-isolates into the genogroup B (Table 3). Although several amino acid changes can be seen in several genogroups, these may also be important to predict the strains´ ability to induce mortality and or morbidity, relatively to the non-virulent reference.Table 3. PRV isolates with data about HSMI mortality grouped into genotypes. FW: freshwater site. SW: seawater site.The result from the epidemiological study showed that the PRV genotype A was associated to higher level of HSMI mortality. The genogroup B was associated with high morbidity (looser fish) and less mortality. The genogroup C was associated with lower mortality and morbidity (looser fish). Accumulated mortality associated with the PRV genotypes is shown in Figure 8, where fig.8A shows the HSMI mortality and Fig 8.B. shows % mortality that is of looser fish, also called morbidity. The figure also show the the 25th and 75th percentiles. A correlation between the genogroups and the mortality from the epidemiological data were confirmed. Regarding figure 8B, the lower and upper border of boxes indicates the 25th and 75th percentiles, respectively and the centerline indicates the 50th percentile. The upper and lower whiskers correspond to the highest and lowest value of the 1.5*IQR (inter-quartile range). The differences between genogroups, are reflected in the 13 amino acid changes shown in Table 2.Example 2:In order to determine whether a fish is infected by a PRV virus causing mortality and/or morbidity, or a nonvirulent virus, primers and probes proving the presence or absence of the SNPs according to the present invention were developed. If one or more of the SNPs are present, then the virus is virulent and will cause morbidity and/or mortality of a fish upon infection. Based on this, 10 different Real Time SNP assays were designed to detect amino acid changes (Table 4). The probe 1 detect the virulent mutation, and probe 2 detect the reference being nonvirulent. All SNP’s can also be detected by sequencing, for the virulence markers M2-320, M3-355 and M3-474 only sequencing are used.Table 4 Primer pairs and probes (assays) for detection of the SNPs of Piscine Orthoreovirus (PRV). Probe 1 (P1) detect virulent strains of the virus, P2 detect the reference virus.Example 3:Test of assays. To validate that the Real Time PCR SNP assays (Example 2) can differentiate between the different groups, 3 assays was tested on field samples from Example 1. The assays SNP S4-T320C, M3-C371T and M3-A1351G, detecting B, C and A respectively, were used.The assays give a differentiation in Ct values and the probe giving the lowest Ct values indicates which SNP mutation that is most frequent in the biologic sample. The detected SNPs are marked in Bold in table 5 below.Table 5: Three assays tested on biological samples, and Ct values from PCR.*ND = Not Detected.This shows that if the P1 probe has the lowest Ct value, when using the SNP assay S4-T320C, the virus is of genotype B. The same is shown for the SNP assays M3 C371T and M3-A1351G; if P1 has the lowest Ct value, the sample is of genotypes C and A respectively.
Claims
Patent claims1. Method for determining virulence of Piscine Orthoreovirus (PRV) in a biological sample from a fish, comprising a step for detecting whether any of the following single nucleotide polymorphisms (SNPs) are present in the genomic material S4-T320C or S4-G754A in SEQ ID NO.4,M2-T580A, or M2-A958G, in SEQ ID NO.5,M3-A280T, M3-C371T, M3-C1064T, M3-A1351G, M3-T1421C or M3-T1687C in SEQ ID NO.6,or the complementary oligonucleotides thereof, wherein the numbering of said positions are in accordance with sequences SEQ ID NO.4, 5 or 6, respectively,wherein presence of at least one SNP confirms that the virus is virulent and will cause morbidity and/or mortality of a fish upon infection.2. Method according to claim 1, comprising a step for isolating the genomic material from the sample, before detecting the SNPs.3. Method according to claim 1 or 2, comprising a further step between isolating and detecting, for sequencing the genomic material.4. Method according to claim 3, wherein the sequencing is performed by a method selected from the group consisting in Illumina (Solexa) sequencing, Roche 454 sequencing, Ion Torrent and SOLiD sequencing.5. Method according to claim 3, wherein the sequencing is performed by a polymerase chain reaction and use of at least one primer.6. Method according to any one of claim 1-5, wherein the step of detecting comprises a polymerase chain reaction and use of at least one primer and/or probe.7. Method according to claims 5 or 6, wherein each primer comprises a sequence of at least 10 consecutive nucleotides selected from one of the sequences of a group consisting of SEQ ID NO.24-25, 28-29, 36-37, 48-49, 52-53, 56-57 and 60-61.8. Method according to any one of claims 5-7, wherein primers are used as primer pairs, selected from a group consisting of the following primer pairs:primers according to SEQ ID NO.24 and 25,primers according to SEQ ID NO.28 and 29,primers according to SEQ ID NO.36 and 37,primers according to SEQ ID NO.48 and 49,primers according to SEQ ID NO.52 and 53,primers according to SEQ ID NO.56 and 57, andprimers according to SEQ ID NO.60 and 61.9. Method according to any one of the preceding claim 6-8, wherein the step of detecting comprises use of probes, wherein binding of a probe comprising a sequence of at least 10 consecutive nucleotides fromSEQ ID NO.26, confirms the virus to have SNP S4-T320CSEQ ID NO.30, confirms the virus to have SNP S4-G754ASEQ ID NO.38, confirms the virus to have SNP M2-T580ASEQ ID NO.50, confirms the virus to have SNP M3-A280TSEQ ID NO.54, confirms the virus to have SNP M3-C371TSEQ ID NO.58, confirms the virus to have SNP M3-A1351GSEQ ID NO.62 or 63, confirms the virus to have SNP M3-T1687C10. Method according to any one of the preceding claims, wherein the presence of mutation M3-A280T and/or M3-A1351G in SEQ ID NO.6 confirms the virus to cause high mortality.11. Method according to any one of the preceding claims, wherein the presence of mutation M3-A280T, M3-C1064T, M3-A1351G, M3-T1421C and M3-T1687C in SEQ ID NO.6 confirms the virus to cause high mortality.12. Method according to any one of claims 1-9, wherein the presence of mutation M3-C371T in SEQ ID NO.6 confirms the virus to cause moderate to low mortality, and morbidity.13. Method according to any one of claims 1-9, wherein the presence of mutation M3-C371T, M3-C1064T and M3-T1421C in SEQ ID NO.6 confirms the virus to cause moderate to low mortality, and morbidity.14. Method according to any one of claims 1-9, wherein the presence of mutation S4-T320C in SEQ ID NO.4 confirms the virus to cause high morbidity.15. Method according to any one of claims 1-9, wherein the presence of mutation S4-G754A in SEQ ID NO.4 confirms the virus to cause high to moderate mortality, and morbidity.16. A primer or probe comprising a sequence of at least 10 consecutive nucleotides selected from the group comprising SEQ ID NO.24-26, 28-30, 36-38, 48-50, 52-54, 56-58 and 60-63.17. Method for determining virulence of Piscine Orthoreovirus (PRV) in a biological sample from a fish, comprising the following steps,a) isolating amino acid sequences of the sample,b) sequencing the amino acid sequence,c) detecting whether any of the following amino acids are present in the amino acid sequences from the sample:- A in position 107 or N in position 252 of SEQ ID NO.1,- I in position 194 or A in position 320 of SEQ ID NO.2, or- L in position 94, V in position 124, L in position 355, V in position 451, T in position 474 or P in position 563 of SEQ ID NO.3,wherein the numbering of said positions are in accordance with the sequences 1, 2 and 3, respectively,wherein presence of at least one the amino acids confirms that the virus is virulent and will cause morbidity and/or mortality of the fish upon infection.18. Method according to claim 17, wherein the presence of amino acid L in position 94, and/or V in position 451 in SEQ ID NO.3 confirms the virus to cause high mortality.19. Method according to claim 17, wherein the presence of L in position 94, L in position 355, V in position 451, T in position 474 or P in position 563 of SEQ ID NO.3 confirms the virus to cause high mortality.20. Method according to claim 17, wherein the presence of V in position 124 of SEQ ID NO.3 confirms the virus to cause moderate mortality, high morbidity.21. Method according to claim 17, wherein the presence of V in position 124, L in position 355, or T in position 474 of SEQ ID NO.3 confirms the virus to cause moderate mortality, high morbidity.22. Method according to claim 17, wherein the presence of A in position 107 of SEQ ID NO.1 confirms the virus to cause high morbidity.23. Method according to claim 17, wherein the presence of N in position 252 of SEQ ID NO.1 confirms the virus to cause moderate mortality, high morbidity.Patentkrav1. Framgangsmåte for å bestemme virulens av Piscine Orthoreovirus (PRV) i en biologisk prøve fra en fisk, omfattende et trinn for å detektere hvorvidt noen av de følgende enkeltnukleotidpolymorfi (single nucleotide polymorphisms) (SNPs) er tilstede i det genomiske materialetS4-T320C eller S4-G754A i SEQ ID NO.4,M2-T580A, eller M2-A1108G i SEQ ID NO.5,M3-A280T, M3-C371T, M3-C1064T, M3-A1351G, M3-T1421C eller M3-T1687C i SEQ ID NO.6,eller de komplementære oligonukleotidene derav, idet nummereringen av posisjonene er i samsvar med henholdsvis sekvenser SEQ ID NO.4, 5 eller 6, idet tilstedeværelse av i det minste en SNP bekrefter at viruset er virulent og vil forårsake sykelighet og/eller dødelighet hos en fisk, ved infeksjon.2. Framgangsmåte i samsvar med krav 1, omfattende et trinn for å isolere det genomiske materialet fra prøven, før detektering av SNPene.3. Framgangsmåte i samsvar med krav 1 eller 2, omfattende et ytterligere trinn mellom isolering og detektering, for sekvensering av det genomiske materialet.4. Framgangsmåte i samsvar med krav 3, idet sekvenseringen utføres ved en framgangsmåte valgt fra gruppen bestående av Illumina (Solexa) sequencing, Roche 454 sequencing, Ion Torrent og SOLiD sequencing.5. Framgangsmåte i samsvar med krav 3, idet sekvensering utføres ved en polymerase-kjedereaksjon og bruk av minst en primer.6. Framgangsmåte i samsvar med et av kravene 1-5, idet trinnet for å detektere omfatter en polymerase-kjedereaksjon og bruk av minst en primer og/ eller probe.7. Framgangsmåte i samsvar med krav 5 eller 6, idet hver primer omfatter en sekvens på minst 10 etterfølgende nukleotider valgt fra en av sekvensene i en gruppe bestående av SEQ ID NO.24-25, 28-29, 36-37, 48-49, 52-53, 56-57 og 60-61.8. Framgangsmåte i samsvar med et av kravene 5-7, idet primerne blir benyttet som primerpar, valgt fra en gruppe bestående av de følgende primerpar:primere i samsvar med SEQ ID NO.24 og 25,primere i samsvar med SEQ ID NO.28 og 29,primere i samsvar med SEQ ID NO.36 og 37,primere i samsvar med SEQ ID NO.48 og 49,primere i samsvar med SEQ ID NO.52 og 53,primere i samsvar med SEQ ID NO.56 og 57, ogprimere i samsvar med SEQ ID NO.60 og 61.9. Framgangsmåte i samsvar med et av de foregående krav 6-8, idet trinnet for å detektere omfatter bruk av prober, idet binding av en probe omfattende en sekvens på minst 10 etterfølgende nukleotider fraSEQ ID NO.26, bekrefter at viruset har SNP S4-T320CSEQ ID NO.30, bekrefter at viruset har SNP S4-G754ASEQ ID NO.38, bekrefter at viruset har SNP M2-T580ASEQ ID NO.50, bekrefter at viruset har SNP M3-A280TSEQ ID NO.54, bekrefter at viruset har SNP M3-C371TSEQ ID NO.58, bekrefter at viruset har SNP M3-A1351GSEQ ID NO.62 eller 63, bekrefter at viruset har SNP M3-T1687C10. Framgangsmåte i samsvar med et av de foregående krav, idet tilstedeværelse av mutasjon M3-A280T og/eller M3-A1351G i SEQ ID NO.6 bekrefter at viruset vil forårsake høy dødelighet.11. Framgangsmåte i samsvar med et av de foregående krav, idet tilstedeværelse av mutasjon M3-A280T, M3-C1064T, M3-A1351G, M3-T1421C og M3-T1687C i SEQ ID NO.6, bekrefter at viruset vil forårsake høy dødelighet.12. Framgangsmåte i samsvar med et av kravene 1-9, idet tilstedeværelse av mutasjon M3-C371T i SEQ ID NO.6, bekrefter at viruset vil forårsake moderate til lav dødelighet, og sykelighet.13. Framgangsmåte i samsvar med et av kravene 1-9, idet tilstedeværelsen av mutasjon M3-C371T, M3-C1064T og M3-T1421C i SEQ ID NO.6, bekrefter at viruset vil forårsake moderat til lav dødelighet, og sykelighet.14. Framgangsmåte i samsvar med et av kravene 1-9, idet tilstedeværelsen av mutasjon S4-T320C i SEQ ID NO.4 bekrefter at viruset vil forårsake høy sykelighet.15. Framgangsmåte i samsvar med et av kravene 1-9, idet tilstedeværelsen av mutasjon S4-G754A i SEQ ID NO.4 bekrefter at viruset vil forårsake høy til moderat dødelighet, og sykelighet.16. Primer eller probe omfattende en sekvens på minst 10 etterfølgende nukleotider valgt fra gruppen omfattende SEQ ID NO.24-26, 28-30, 36-38, 48-50, 52-54, 56-58 og 60-63.17. Framgangsmåte for bestemme virulens av Piscine Orthoreovirus (PRV) i en biologisk prøve fra en fisk, omfattende de følgende trinn;a) isolere aminosyre-sekvensen av prøven,b) sekvensere aminosyre-sekvensen,c) detektere hvorvidt noen av de følgende aminosyrene er tilstede i aminosyre-sekvensene fra prøven:- A i posisjon 107 eller N i posisjon 252 av SEQ ID NO.1,- I i posisjon 194 eller A i posisjon 320 av SEQ ID NO.2, eller- L i posisjon 94, V i posisjon 124, L i posisjon 355, V i posisjon 451, T i posisjon 474 eller P i posisjon 563 av SEQ ID NO.3,idet nummereringen av nevnte posisjoner er i samsvar med henholdsvis sekvens 1, 2 og 3,idet tilstedeværelse av minst en av aminosyrene bekrefter at viruset er virulent og vil forårsake sykelighet og/ eller dødelighet hos fisken, ved infeksjon.18. Framgangsmåte i samsvar med krav 17, idet tilstedeværelsen av aminosyre L i posisjon 94, og/ eller V i posisjon 451 i SEQ ID NO.3 bekrefter at viruset vil forårsake høy dødelighet.19. Framgangsmåte i samsvar med krav 17, idet tilstedeværelsen av av L i posisjon 94, L i posisjon 355, V i posisjon 451, T i posisjon 474 eller P i posisjon 563 av SEQ ID NO.3 bekrefter at viruset vil forårsake høy dødelighet.20. Framgangsmåte i samsvar med krav 17, idet tilstedeværelsen av V i posisjon 124 av SEQ ID NO.3 bekrefter at viruset vil forårsake moderate dødelighet, høy sykelighet.21. Framgangsmåte i samsvar med krav 17, idet tilstedeværelsen av V i posisjon 124, L i posisjon 355, eller T i posisjon 474 av SEQ ID NO.3 bekrefter at viruset vil forårsake moderate dødelighet, høy sykelighet.22. Framgangsmåte i samsvar med krav 17, idet tilstedeværelsen av A i posisjon 107 av SEQ ID NO.1 bekrefter at viruset vil forårsake høy sykelighet.23. Framgangsmåte i samsvar med krav 17, idet tilstedeværelsen av N i posisjon 252 av SEQ ID NO.1 bekrefter at viruset vil forårsake moderat dødelighet, høy sykelighet.
Drawings

Priority


No priority

Patent classes


IPC classesC07K 14/14A61K 39/15C12Q 1/70C12N 15/46CPC classesC07K 14/14A61K 39/15C12Q 1/70C12N 2720/12211C12N 2720/12221C12N 2720/12222C12N 2720/12243C12N 2720/12271

Citations


NO 20161983 A1 (A1)WO 2016075277 A1 (A1)WO 2018138527 A1 (A1)PALACIOS GUSTAVO ET AL., «Heart and skeletal muscle inflammation of farmed salmon is associated with infection with a novel reovirus» PLoS ONE, vol. 5, nr. 7, 2010, side 1-7 (e11487) ()

Applicants, owners and inventors


Owners
PatoGen AS
Postboks 548 6001 ÅLESUND NO (Ã…LESUND Municipality, Møre og Romsdal county)Org. number: 985525331
Inventors
Morten Lund
Nordre Sprovei 29 1454 FAGERSTRAND NO (NESODDEN Municipality, Akershus county)
Håvard Aanes
Sigurd Hoels Vei 116 0655 OSLO NO (OSLO Municipality, Oslo county)
Gordon Richie
Skeiestraen 21 4083 HUNDVÅG NO (STAVANGER Municipality, Rogaland county)
Vidar Teis Aspehaug
Fagerliveien 15 6008 ÅLESUND NO (Ã…LESUND Municipality, Møre og Romsdal county)
Linda Ramsevik Teigene
Dagerskrybba 5 6013 ÅLESUND NO (Ã…LESUND Municipality, Møre og Romsdal county)
Magnus Andreas Devold
Vassetvegen 67 6030 LANGEVÅG NO (SULA Municipality, Møre og Romsdal county)

Agent


ACAPO ONSAGERS AS
ACAPO ONSAGERS AS

Org. number: 932214636

Name and address are automatically synchronized with the Brønnøysund Register Centre.

Open in The Brønnøysund Register Centre
Edvard Griegs vei 1 5059 BERGEN NO (BERGEN Municipality, Vestland county)
Org. number: 932214636
Reference: P17640NO00

Status history


Payment history


Oppositions and appeals


No oppositions or appeals

Administrative limitation


No administrative limitation

Liens and licences


No liens or licenses registered

Gazette entries


No Gazette entries foundOnly events from 2024.03.04 and onwards are shown.